デフォルト表紙
市場調査レポート
商品コード
1622120

子宮内膜症薬の世界市場規模:製品別、用途別、地域別、範囲および予測

Global Endometriosis Drugs Market Size By Product(Hormonal Therapy, Add-back Medication, Progestogens), By Application(Hospitals, Clinics, Research Institutes), By Geographic Scope And Forecast


出版日
ページ情報
英文 202 Pages
納期
2~3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.26円
子宮内膜症薬の世界市場規模:製品別、用途別、地域別、範囲および予測
出版日: 2024年08月15日
発行: Verified Market Research
ページ情報: 英文 202 Pages
納期: 2~3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

子宮内膜症薬の市場規模と予測

子宮内膜症薬の市場規模は、ここ数年大幅な成長率で急成長しており、2021年から2028年の市場規模・推計・予測においても、市場は大きく成長すると予測されます。

子宮内膜症の有病率の高まりは、子宮内膜症治療に関連する女性の意識の向上にもつながっています。さらに、子宮内膜症の発生件数の大幅な増加、研究開発への投資も、この市場の成長機会をますます拡大しています。子宮内膜症薬の世界市場レポートは、市場の全体的な評価を提供します。主要セグメント、動向、市場促進要因、抑制要因、競合情勢、市場で重要な役割を果たしている要因などを包括的に分析しています。

世界の子宮内膜症薬市場の定義

子宮内膜症は慢性的な痛みを伴う疾患で、子宮を外形的に囲む組織(卵管、卵巣、子宮を支える靭帯に見られる)が破裂し、炎症や内出血を引き起こします。これにより、不妊症、癒着、疼痛、瘢痕組織の形成、腸管障害を引き起こすことがあります。この病気の症状には、生理中の排便痛、性行為時の痛み、生理前や生理中の痛み、不妊症、生理中の排尿痛、疲労感、下痢、吐き気、便秘などの胃腸障害などがあります。子宮内膜症は生涯続く疾患であるため、疾患の程度、疼痛の程度、妊娠の可能性に基づいて、管理するための医療戦略を立てることが重要です。

子宮内膜症の治療には、疼痛治療薬、ホルモン避妊薬、黄体ホルモンのみの避妊薬、ゴナドトロイン放出ホルモン(GnRH)アナログ薬、アロマターゼ阻害薬など、さまざまな薬があります。アロマターゼは、体内のエストロゲン産生を高める化学物質です。アロマターゼ阻害剤はこれを阻害し、エストロゲンのレベルを下げます。これらの薬は、子宮内膜症の治療に日常的に使用されることはありません。一方、ホルモン避妊薬は、一般的に子宮内膜症に伴う多量の月経出血を止めることができます。

世界の子宮内膜症薬の市場概要

女性の健康に対する関心の高まりは、予測期間中の子宮内膜症薬の市場規模の成長を後押しする重要な要因です。様々な政府当局や組織は、無自覚や無教育の課題問題を克服するために、意識向上に取り組んでいます。女性の健康への注目は、世界の子宮内膜症薬市場の拡大につながります。さらに、この疾患の発生が大幅に増加し、研究開発への投資は、世界の子宮内膜症薬市場の成長を推進する上で積極的に期待しています。

市場全体の成長を阻害する一定の抑制要因と課題が直面しています。例えば、子宮内膜症薬市場は高コストのホルモンベースの治療薬が主流であり、これは患者にとって重大な懸念であり、市場推計・予測期間中の成長を鈍化させると予測されています。また、子宮内膜症や子宮内膜がんなど、さまざまな婦人科がんの適応症に関する認知度の低さが、市場成長の課題となっています。さらに、この疾患の診断にかかる時間は長く、研究者らは7~9年と推定しています。今のところ、医療インフラやハイテク医療機器・装置の不足と相まって、非侵襲的な診断検査は利用できないです。これらは、世界の子宮内膜症薬市場全体の成長を妨げる潜在的な要因です。

目次

第1章 子宮内膜症薬の世界市場:イントロダクション

  • 市場概要
  • 調査範囲
  • 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

  • データマイニング
  • バリデーション
  • 一次インタビュー
  • データソース一覧

第4章 子宮内膜症薬の世界市場展望

  • 概要
  • 市場力学
  • 促進要因
  • 抑制要因
  • 機会
  • ポーターのファイブフォースモデル
  • バリューチェーン分析

第5章 子宮内膜症薬の世界市場:製品別

  • ホルモン療法
  • アドバック薬
  • 黄体ホルモン
  • 漢方薬

第6章 子宮内膜症薬の世界市場:用途別

  • 病院
  • 診療所
  • 研究機関

第7章 子宮内膜症薬の世界市場:地域別

  • 北米
  • 米国
  • カナダ
  • メキシコ
  • 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
  • アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
  • 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 子宮内膜症薬の世界市場:競合情勢

  • 概要
  • 各社の市場ランキング
  • 主な開発戦略

第9章 企業プロファイル

  • AbbVie
  • Astellas Pharma
  • AstraZeneca
  • Debiopharm Group
  • Evotec AG
  • Kissei Pharmaceutical
  • Neurocrine Biosciences
  • ObsEva
  • Pfizer
  • Repros Therapeutics
  • Roivant Sciences GmbH
  • Takeda Pharmaceutical Company Limited
  • ValiRx

第10章 付録

  • 関連レポート
目次
Product Code: 16426

Endometriosis Drugs Market Size And Forecast

Endometriosis Drugs Market size is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2021 to 2028.

The growing prevalence of endometriosis has also lead to higher awareness among women related to endometriosis treatment. Moreover, the significant rise in the occurrence of this disease, investment in research, and development are also increasingly expanding growth opportunities in this market. The Global Endometriosis Drugs Market report provides a holistic evaluation of the market. The report offers comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Endometriosis Drugs Market Definition

Endometriosis is a chronic and painful condition, where the tissues that outline the uterus externally (found in the fallopian tubes, ovaries, and ligaments that support the uterus) ruptures and causes inflammation and internal bleeding. This can cause infertility, adhesions, pain, scar tissue formation, and bowel problems. Symptoms of the disease include painful bowel movements during periods, pain with sex, pain before and during periods, infertility, painful urination during periods, fatigue, and other gastrointestinal problems such as diarrhea, nausea, and constipation. Endometriosis is a lifelong condition so it is important to develop a medical strategy to manage it based on the extent of the disease, severity of pain, and potential plans for pregnancy.

There are various medications available to cure endometriosis such as Pain Medication, Hormone Birth Control, Progestin-only contraceptives, Gonadotroin-releasing Hormone (GnRH) Analogues, and Aromatase Inhibitors. Aromatase is a chemical that boosts your body's estrogen production. Aromatase inhibitors block it, which lowers your estrogen level. These medicines aren't routinely used to treat endometriosis. Whereas, hormone birth control can stop the heavy menstrual bleeding that generally accompanies endometriosis.

Global Endometriosis Drugs Market Overview

The growing focus emphasis on women's health is the key factor in boosting the growth of the endometriosis drugs market size during the forecast period. The various governmental authorities and organizations are working to raise awareness to overcome unawareness and uneducated challenges problems. The focus on women's health will lead to the expansion of the global endometriosis drugs market. Moreover, the significant rise in the occurrence of this disease, investment in research, and development has positively anticipated in propelling the growth of the global Endometriosis drugs market.

There are certain restraints and challenges faced which will hinder the overall market growth. The factors such as the endometriosis drug market are dominated by high-cost hormone-based therapeutics, which is a significant concern for patients and is estimated to sluggish growth during the forecast period. Lack of awareness about various gynecological cancer indications such as endometriosis and endometrial cancer was a challenge for the growth of the market. Further, the time that is taken to diagnose the disease is high, which is estimated by the researchers as seven to nine years. Till now, there are no diagnostic tests available that are non-invasive coupled with a lack of medical infrastructure and hi-tech medical equipment and devices. These are the potential restraints hampering the overall growth of the global Endometriosis drugs market.

Global Endometriosis Drugs Market: Segmentation Analysis

Global Endometriosis Drugs Market is segmented based on Product, Application, And Geography.

Endometriosis Drugs Market by Product

  • Hormonal Therapy
  • Add-back Medication
  • Progestogens
  • Chinese Herbs

Based on Product, the market is bifurcated into Hormonal Therapy, Add-back Medication, Progestogens, and Chinese Herbs. The hormone therapy segment holds the largest market share for the forecast period. It is considered the most effective treatment for endometriosis as it can reduce or effectively eliminate the pain associated with the condition compared with analgesics. This factor will increase sales of medications that act on hormones associated with the condition. The sales of hormonal medications will further improve with the introduction of novel drug delivery systems.

Endometriosis Drugs Market by Application

  • Hospitals
  • Clinics
  • Research Institutes

Based on Application, the market is bifurcated into Hospitals, Clinics, Research Institutes. The hospital segment is estimated to witness the highest CAGR for the forecast period. The factors that can be attributed to the growing prevalence of endometriosis and rise in the occurrence of this disease are fueling the demand for this segment.

Endometriosis Drugs Market by Geography

On the basis of regional analysis, the Global Endometriosis Drugs Market is classified into

North America

Europe

Asia Pacific

Rest of the world

North America holds the largest market share. The increasing treatment costs, higher disability losses, and the large number of reproductive populations that are suffering from endometriosis. High awareness among people, strong governmental initiatives and ongoing projects will boost the market in this region.

Key Players

The market analysis entails a section solely dedicated to major players in the Global Endometriosis Drugs Market wherein our analysts provide an insight into the financial statements of all the major players along with its key developments product benchmarking and SWOT analysis. The company profile section also includes a business overview and financial information. The companies that are provided in this section can be customized according to the client's requirements.

  • AbbVie
  • Astellas Pharma
  • AstraZeneca
  • Debiopharm Group
  • Evotec AG
  • Kissei Pharmaceutical
  • Neurocrine Biosciences
  • ObsEva
  • Pfizer
  • Repros Therapeutics
  • Roivant Sciences GmbH
  • Takeda Pharmaceutical Company Limited
  • ValiRx

Key Developments

Partnerships, Collaborations and Agreements

  • The US Food and Medication Administration (FDA) granted AbbVie Inc. approval for their drug ORILISS in July 2018. (elagolix). This is a GnRH-type medication that is used to relieve endometriosis pain that is severe to moderate.
  • In July 2017, Evotec AG reported that a programme from their multi-target endometriosis alliance with Bayer had moved into Phase I clinical development for the treatment of endometriosis, triggering a milestone payment to Evotec.
  • In January 2021, Myovant Sciences and Pfizer Inc. announced that the Phase 3 SPIRIT long-term extension study of the investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with endometriosis found clinically significant reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain over a year.

Product Launches and Product Expansions

  • In October 2018, Astellas Pharma Inc. reported that building and remodelling of new facilities for the research, development, and manufacture of novel pharmaceuticals employing new Modality/Technology had commenced in Toyama and Tsukuba, Japan, as well as Massachusetts, USA.

TABLE OF CONTENTS

1. Introduction of Global Endometriosis Drugs Market

  • Overview of the Market
  • Scope of Report
  • Assumptions

2. Executive Summary

3. Research Methodology of Verified Market Research

  • Data Mining
  • Validation
  • Primary Interviews
  • List of Data Sources

4. Global Endometriosis Drugs Market Outlook

  • Overview
  • Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
  • Porters Five Force Model
  • Value Chain Analysis

5. Global Endometriosis Drugs Market, By Product

  • Hormonal Therapy
  • Add-back Medication
  • Progestogens
  • Chinese Herbs

6. Global Endometriosis Drugs Market, By Application

  • Hospitals
  • Clinics
  • Research Institutes

7. Global Endometriosis Drugs Market, By Geography

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • UK
  • France
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Rest of Asia Pacific
  • Rest of the World
  • Latin America
  • Middle East & Africa

8. Global Endometriosis Drugs Market Competitive Landscape

  • Overview
  • Company Market Ranking
  • Key Development Strategies

9. Company Profiles

  • AbbVie
  • Astellas Pharma
  • AstraZeneca
  • Debiopharm Group
  • Evotec AG
  • Kissei Pharmaceutical
  • Neurocrine Biosciences
  • ObsEva
  • Pfizer
  • Repros Therapeutics
  • Roivant Sciences GmbH
  • Takeda Pharmaceutical Company Limited
  • ValiRx

10. Appendix

  • Related Reports